A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)

Condition:   HIV-1 Infection Interventions:   Drug: DOR/ISL;   Drug: BIC/FTC/TAF;   Drug: Placebo to BIC/FTC/TAF;   Drug: Placebo to DOR/ISL Sponsor:   Merck Sharp & Dohme LLC Not yet recruiting

Source: ClinicalTrials.gov - November 30, 2022 Category: Research Source Type: clinical trials